Abstract

Introduction

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies, with most patients having advanced disease at the time of diagnosis [1, 2]. Chemotherapy is the main treatment strategy for advanced PDAC, capable of transforming initially unresectable PDAC into resectable cancer [3, 4]. Due to the toxic side effects of the fluorouracil plus irinotecan plus oxaliplatin plus leucovorin (FOLFIRINOX) regimen, the Nab-paclitaxel plus gemcitabine regimen (AG regimen) is considered the best option in Asia [5, 6]. Nonetheless, the emergence of primary resistance to the AG regimen poses a significant clinical challenge, affecting approximately 40–60% of patients [7]. Currently, most studies focus on screening which patients are suitable for AG chemotherapy [8]. However, new methods to achieve chemotherapy sensitization in patients resistant to the AG regimen are overlooked. Recent research tried to combine immunotherapy with an AG regimen, but the results were unsatisfactory due to the low responsiveness of PDAC to immunotherapy [9, 10]. Therefore, the development of clinically effective AG re-sensitization therapies is an important clinical challenge.

Signaling pathway activation is closely related to chemotherapy resistance [11, 12]. The classic PI3K/Akt pathway is the core pathway among various tumor-related signaling pathways [13, 14], and its abnormal activation commonly detected in PDAC cases can greatly promote PDAC chemotherapy resistance [12, 15]. Therefore, using a combination of inhibitors targeting this pathway is a potential strategy to achieve chemotherapy sensitization. Previous studies have shown that chemotherapy combined with PI3K/Akt pathway inhibitors (e.g., Everolimus, BKM120, and Duvelisib) is an effective treatment strategy for breast cancer, head and neck squamous cell carcinoma, and non-Hodgkin lymphoma [16–18]. Preclinical studies showed that chemotherapy combined with PI3K/Ak/mTOR inhibitors (Everolimus and Sirolimus) may improve treatment efficacy for GEM-resistant PDAC cases [19–21]. However, clinical trial results for Everolimus did not show anti-tumor effects in patients with GEM-refractory metastatic PDAC [22], and another clinical study showed strong grade 3–4 adverse reactions during Everolimus administration [23]. In a phase II study of Sirolimus combined with GEM for the treatment of advanced PDAC, although 34.6% of patients achieved partial response, it greatly increased the risk of bone marrow suppression and infection [24]. Therefore, currently, in clinical practice, the use of the combination strategy involving PI3K/Akt pathway inhibitor-sensitizing chemotherapy is very limited. The search for safe and reliable PI3K/Akt pathway inhibitors is important in sensitizing PDAC to chemotherapy.

“Conventional drug in new use” is an important strategy for research and treatment of diseases at this stage, because a large amount of data supports drug safety with this strategy [25–27]. Our team previously focused on sulindac K-80003, a derivative of the clinical anti-inflammatory drug sulindac. As an inhibitor of the PI3K/Akt pathway, it has more reliable biological safety and precise targeting [28], as demonstrated in studies related to hepatocellular carcinoma and colorectal cancer [28, 29]. However, its potential therapeutic effects and whether sulindac K-80003 can promote the sensitization of pancreatic cancer to the AG regimen on PDAC are unknown. For the first time, we investigated a combination of sulindac K-80003 with the AG regimen in patient-derived organoid (PDO) and PDO xenograft (PDOX) treatment models from PDAC patients and demonstrated a positive therapeutic response. Given this promising finding, we sought to identify biomarkers to predict which patients may benefit from sulindac K-80003 combination therapy. Based on the characteristics of non-coding circular RNA (circRNA), which include a stable structure, a long half-life, and easy detection [30, 31], we have identified a circRNA as a potential biomarker for sulindac K-80003-promoted AG sensitization [32, 33]. Previous studies have reported that circRNAs can be highly powerful predictors of chemotherapy sensitivity, such as circ-DOPEY2 for cisplatin chemotherapy in esophageal cancer [34] and circ-CREIT for DOX in breast cancer [35]. Based on these studies we hypothesized that a circRNA may serve as a predictor for sulindac K-80003 application in PDAC chemotherapy.

In our study, based on multi-omics data from RNA-seq, protein sequencing (Protein-seq), multiplex immunofluorescent staining (mIFS), 3D-cell in vitro models, and in vivo PDO models of AG chemotherapy-resistant PDAC (Fig. 1A), we identified the critical role of abnormal activation of the PI3K/Akt signaling pathway in chemotherapy-resistant patients. Given this characteristic, we confirmed that sulindac K-80003 can promote chemotherapy sensitivity in half of AG chemotherapy-resistant patients through a prospective internal PDAC cohort. Furthermore, these results were verified using retrospective internal and external PDAC cohort organoids. Finally, an exploration of clinical sensitization biomarkers revealed that the circular RNA cFAM124A is more sensitive and convenient for predicting sulindac K-80003 sensitization than the classic markers p-Akt (Thr308) and p-Akt (Ser473).

Open in a separate window

Fig. 1

PI3K/Akt pathway plays a vital role in the resistance of PDAC to GEM-based chemotherapy. A, Overall experimental scheme for this study. B, Complex heatmap showing differentially expressed genes (DEGs) and distribution of clinical parameters between AG-sensitive and AG-resistant PDAC. C, KEGG pathway enrichment analysis for the upregulated DEGs in the RNA-seq comparing the AG-resistant group and AG-sensitive group. D, KEGG pathway enrichment analysis of external RNA-seq data, SRP303224. E, Representative hematoxylin and eosin (H&E) staining images of AG-sensitive and AG-resistant PDAC and patient-derived organoids (PDOs). Scale bar, 100 μm. F, IC₅₀ values for 10 PDOs after GEM treatment. G-H, Representative images of PDOs from PDO-AGS and PDO-AGR groups. PDOs treated for 48 h with nab-paclitaxel (10nM) and gemcitabine (30nM). Live/Dead cell viability staining showing live cells stained with calcein-AM (green) and dead cells with Ethidium-1 (red). Scale bar, 50 μm. I, RNA-seq results for PDO-AGS and PDO-AGR groups from PDOs. J, Heatmap showing DEGs between PDO-AGS and PDO-AGR groups. K, KEGG pathway enrichment analysis for upregulated DEGs in the RNA-seq comparing the PDO-AGS group and PDO-AGR groups. L, Representative images of H&E and IHC staining for p-Akt (Thr308) in PDOs from PDO-AGS and PDO-AGR groups

Results

K-80003 enhances sensitivity to AG chemotherapy in pre-clinical models of AG-resistant unresectable PDAC cases

Given that the PI3K/AKT pathway plays a central role in the resistance of PDAC to the AG regimen, targeting this pathway in tumor cells was expected to overcome PDAC resistance to the AG regimen. However, existing PI3k/Akt inhibitors are not suitable for clinical applications due to their extensive toxicity and side effects. Therefore, we shifted our attention to the “conventional drug in new use” approach, which is also an important new strategy for developing disease treatments [25], because the safety of old drugs for use in humans has been fully proven. Our team previously focused on sulindac K-80003, a derivative of the clinical anti-inflammatory drug sulindac, as an effective PI3K/Akt pathway inhibitor. K-80003 has more reliable biological safety and superior specificity in targeting PI3K/AKT. Therefore, we explored the potential of sulindac K-80003 to overcome AG resistance in a prospectively constructed PDO-AGR group. Surprisingly, among the 5 PDOs in the AG-resistant group, sulindac K-80003 sensitized 3 PDOs (PDO11#, PDO17#, and PDO18#) to AG chemotherapy. To further analyze whether sulindac K-80003 produces similar effects in vivo, we established an orthotopic pancreatic cancer model by injecting PDOs (PDOX model). Consistent with the in vitro results, sulindac K-80003 restored sensitivity to AG significantly shrunk tumors arising and prolonged the median survival in the corresponding PDOX model (Fig. 2A-F, Fig. S1B). In addition, western blotting analysis further demonstrated that sulindac K-80003 could inhibit the activation of PI3k/Akt signals for patients who respond to the sensitization effect of K-80003 (Fig. S1C). These important findings suggest that sulindac K-80003 is a potential drug that could enhance the sensitivity of some AG-resistant PDAC cases to AG chemotherapy.

Open in a separate window

Fig. 2

K-80003 can enhance the sensitivity of some AG-resistant PDAC patients to AG chemotherapy. A, Method used to apply different treatments to PDO-AGR in vitro and quantitation of PDO fluorescence. Method used for corresponding PDOX treatments in vivo. B-F, Representative images of different PDO-AGRs that received different treatments. PDOs in each group treated for 48 h with saline or AG (Nab-paclitaxel 10nM plus GEM 30nM) or K-80003 (5 nM) or AG (Nab-paclitaxel 10nM plus GEM 30nM plus K-80003 5 nM). Live cells stained with calcein-AM (green), and dead cells with ethidium-1 (red). Quantitative data are shown on the right. Tumors from different groups of PDOXs received different treatments from weeks 2 after orthotopic xenograft injection of 1 million corresponding PDOs. Mice were treated with saline, K-80003 (20 mg/kg, twice weekly; bule arrows), the dual combination of gemcitabine (25 mg/kg, weekly), and nab-paclitaxel (15 mg/kg, weekly; red arrows), or the triple combination of gemcitabine and nab-paclitaxel (as dosed for the monotherapies) plus K-80003 for 3 weeks. Tumors were harvest at 3 weeks after injection. Fluorescence of tumors from mice in the different groups (5 mice per group). Survival curves for mice that received different treatments (5 mice per group). Not significant (ns), *P<0.05; **P<0.01; ***P<0.001

Next, we evaluated the biosafety of sulindac K-80003 in vivo. During use, the body weight of mice in different treatment groups was similar, and the use of sulindac K80003 did not significantly change the body weight of mice. After 1 month of treatment with sulindac K-80003, the blood biochemical parameters of alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood urea nitrogen (BUN), and creatinine were significantly higher than those in the saline-treated group (Fig. S1D-S1G). However, no histopathological abnormalities were detected in the heart, liver, spleen, lung, or kidney of mice in the AG plus K-80003 group (Fig. S1H-S1I). These results indicate that the K-80003 combined AG regimen has no significant drug toxicity in vivo and has a good safety profile.

K-80003 enhances sensitivity to AG chemotherapy in pre-clinical models of AG-resistant resectable PDAC cases

Considering the limited sample size of prospectively constructed advanced PDOs; to further illustrate the efficacy of sulindac K-80003 for sensitization to AG chemotherapy and to eliminate accidental errors, we conducted a retrospective study using the PDO biobank from which surgically resected tissue samples from PDAC patients are more readily available. First, we grouped patients who underwent radical surgical resection according to the international definition of drug-resistant cases after surgery for pancreatic cancer [40]. With standard GEM-based adjuvant chemotherapy after surgery, patients who developed recurrence or distant metastasis within 6 months were considered to be chemotherapy-resistant. Based on this standard, we randomly selected 12 drug-resistant PDOs from the internal biobank and randomly obtained 11 drug-resistant PDOs from the external biobank for recovery culture as shown in Fig. 3A. First, we compared the basic clinical information of the corresponding patients in the internal PDO cohort and the external PDO cohort. As shown in Fig. 3B and Table S2, the two cohorts showed significant differences in age, gender, and tumor stage, and the two cohorts had similar recurrence-free survival (RFS) (Fig. 3C).

Open in a separate window

Fig. 3

Response status of AG-resistant PDAC with K-80003 treatment from in-house and external cohorts. A, Flow chart for screening PDAC patients for K80003 sensitization AG regimen. B, Complex heatmap showing distribution of clinical parameters between in-house cohort and external cohort of AG-resistant PDAC. C, Kaplan–Meier overall survival (PFS) curves between in-house cohort and external cohort of AG-resistant PDAC. D, Representative HE staining images of 12 AG-resistant PDAC samples and PODs from in-house cohort, and ability of K-80003 to sensitize samples to AG chemotherapy. E, Weight of tumors from mice in the different groups (5 mice per group), and survival curves for mice that received different treatments (5 mice per group). Tumors from different groups of PDOXs received different treatments from weeks 2 after orthotopic xenograft injection of 1 million corresponding PDOs. Mice were treated with saline, the dual combination of gemcitabine (25 mg/kg, weekly), and nab-paclitaxel (15 mg/kg, weekly; red arrows), or the triple combination of gemcitabine and nab-paclitaxel (as dosed for the monotherapies) plus K-80003 (20 mg/kg, twice weekly; blue arrows) for 3 weeks. Tumors were harvest at 3 weeks after treatment. Survival curves for mice that received different treatments (5 mice per group). F, Representative HE staining images of 11 AG-resistant PDAC-derived PDOs in external cohort, and ability of K-80003 to sensitize them to AG chemotherapy. G, Weight of tumors from mice in the different groups (5 mice per group), and survival curves for mice that received different treatments (5 mice per group). Not significant (ns), *P<0.05; **P<0.01; ***P<0.001

Similarly, we constructed the PDOX models by injecting the PDOs, which were treated with three solutions: saline, AG, or AG plus K-80003. In the internal cohort, we found that AG combined with K-80003 treatment significantly shrunk tumors arising from 6 PDOs (PDO#II, PDO#III, PDO#VI, PDO#VIII, PDO#XI, and PDO#XII) and extended the median survival time. In contrast, the other 6 PDOs showed little response after treatment with AG combined with sulindac K-80003 (Fig. 3D-E). In the external cohort, sulindac K-80003 demonstrated the ability to sensitize 5 PDOs to AG chemotherapy (PDO#a, PDO#c, PDO#f, PDO#g, and PDO#j) (Fig. 3F-G). These results validated sulindac K-80003 as an effective AG chemosensitizing drug and promoted sensitization in half (14/28) of patients with AG-resistant PDAC in internal and external cohorts. However, considering that half of the patients still had a limited sensitization response, it is necessary to find appropriate response prediction markers to achieve patient stratification for treatment.

circRNA screening for biomarkers of the ability of K-80003 to sensitize PDAC to AG

We next used RNA-Seq analysis from PDOs to explore potential circRNA biological markers associated with the ability of sulindac K-80003 to sensitize PDAC to the AG regimen. The screening process is illustrated in Fig. 4A. First, a total of 46 differentially expressed circRNAs were identified, of which 25 were up-regulated and 21 were down-regulated (Fig. 4B). The up-regulated/down-regulated top 5 circRNAs were verified by PCR separately (Fig. 4C). Notably, this expression pattern was consistent with the PATU8988T and MiaPaCa-2 GEM-resistant models, which we constructed under continuous and progressive stimulation with GEM, and their resistance to GEM was confirmed using CCK-8 experiments and colonization experiments (Fig. 4C and Fig. S2A-S2C). Secondly, we defined the relative circRNA^hi and circRNA^lo in 10 cases using the median expression value as the cut-off value. Then, GSEA was performed on the read mRNA in the RNA-seq comparing the circRNA^hi and circRNA^lo groups to confirm the association between the expression of circRNA and the PI3K/AKT pathway and to calculate gene set enrichment analysis (GSEA) enrichment scores and Pearson correlation analysis (Fig. 4D and E and Fig. S2D). Through these studies, we identified four circRNAs as our screening indicators. Finally, we overexpressed these four circRNAs individually in PDAC cell lines to verify their drug resistance capabilities in a 3D tumor microsphere apoptosis staining assay. The experimental results show that hsa_circ_008816, hsa_circ_0030292, and hsa_circ_000620 overexpression resulted in GEM resistance, and thus, we further treated the cells expressing the GEM resistance circRNAs with additional K-80003 to examine whether their GEM-resistance could be resensitized by K-80003. We found that only overexpression of hsa_circ_0030292 (cFAM124A) had both abilities (Fig. 4F), and that cFAM124A was most closely related to activation of the PI3K/Akt pathway (Fig. 4E).

Open in a separate window

Fig. 4

cFAM124A is a potential biomarker for the ability of K-80003 to increase AG sensitivity of PDAC. A, Flowchart for screening for K-80003 response markers. B, Volcano plot showing upregulated and downregulated circRNAs between PDO-AGS and PDO-AGR groups. C, RT-qPCR detection of the expression of 10 relevant circRNAs in PDAC PDOs and cells. D, GSEA of 10 circRNAs demonstrating enrichment of DEGs in the PI3K/Akt pathway. E, Pearson correlation analysis between PI3K/Akt signaling pathway marker expression and the 10 circRNAs and number of related genes. F, Necrosis in 3D tumor microspheres based on propidium iodide (PI) staining (red) and its quantification after treatment with Gem (1 µM) and/or K-80003 (5 nM). Scale bar, 100 μm. G, Representative H&E and IHC staining for p-Akt (Thr308) and FISH staining for cFAM124A in samples from GEM-sensitive (Gem-S) and GEM-resistant (Gem-R) patients. Quantification of p-Akt (Thr308) staining in PDAC tissues collected from Gem-S and Gem-R groups. Quantification of cFAM124A staining in PDAC tissues collected from Gem-S and Gem-R groups. Pearson correlation analysis between p-Akt (Thr308) expression and cFAM124A expression. H, Kaplan–Meier OS and PFS curves according to cFAM124A expression for PDAC patients in Table S3 (n=132). Not significant (ns), *P<0.05; **P<0.01; ***P<0.001

According to the circBase database, cFAM124A is formed by the circularization of exon 3 of the FAM124A gene and is 473 nt in length. We determined the head-to-tail splicing sites of cFAM124A through Sanger sequencing (Fig. S2E), and our results confirm that cFAM124A has the basic characteristics of a circRNA. cFAM124A was more resistant to RNase R degradation than the linear form of FAM124A mRNA (Fig. S2F-S2G, Fig. S2I). As shown in Fig. S2H, cFAM124A could only be amplified from cDNA rather than gDNA, indicating that cFAM124A was a back-splicing product of the pre-mRNA. In addition, qRT-PCR and fluorescence in situ hybridization (FISH) analysis showed that cFAM124A was mainly localized in the cytoplasm, with a small amount present in the nucleus (Fig. S2J-S2K).

For future research, we established PATU8988T and MiaPaCa-2 cell lines in which cFAM124A was overexpressed. PATU8988T-GR and MiaPaCa-2-GR cell lines with knockdown of cFAM124A but no change in FAM124A cellular gene expression (Fig. S3A-S3B). In addition, we further examined the expression levels of cFAM124A in both the in-house cohort and external cohort PDOs (Fig. 3D and F), and the results reveals its predictive accuracy for the ability of K-80003 to sensitize PDAC to AG. We defined the cFAM124A^hi and cFAM124A^lo cases using the median expression value as the cut-off value. There were 9 cases of response among the 12 cFAM124A^hi PDOs (9/12) and 8 of no-response among the 11 cFAM124A^lo PDOs (8/11), for a true positive ratio=75% (Fig. S3C).

To further validate this finding, we investigated the activation of PI3K/Akt and expression of cFAM124A in our in-house PDAC cohort who received GEM-based chemotherapy by IHC staining and FISH. Patients were assigned to a GEM-based resistant (Gem-R) group based on RFS<12 months. Our results showed that cFAM124A expression and activation of the PI3K/Akt pathway were robustly increased in the GEM-based resistant group (Fig. 4G). Furthermore, cFAM124A expression levels were positively correlated with activation of the PI3K/Akt pathway (Fig. 4G). cFAM124A expression was closely correlated with a higher CA199 level, poor differentiation, similar American Joint Committee on Cancer (AJCC) stage, and worse survival (Fig. 4H and Table S3) within the PDAC cohort in our center. Our findings suggest that only cFAM124A is associated with resistance to gemcitabine and response with K-80003, while the other four upregulated circRNAs were not associated with resistance to gemcitabine or cannot predict the response with K-80003. Also, cFAM124A is closely associated with PI3K/Akt pathway activation, and thus, we hypothesized that it may serve as a marker to identify K-80003-associated AG sensitivity in resistant PDAC.

cFAM124A is the best biomarker for the ability of K-80003 to sensitize PDAC to AG

We next focused on identifying which marker is the best marker for the ability of sulindac K-80003 to sensitize PDAC to AG chemotherapy. Sulindac K-80003 inhibits the activation of tumor-specific PI3K/Akt signaling by preventing the binding of tRXRα to the p85α subunit of PI3K [41]. Here, we further prove that this phenomenon also exists in PDAC through co-IP, as shown in Fig. S4A. Theoretically, sulindac K-80003 is most suitable for patients with high expression levels of tRXRα and PI3K/Akt activation markers. However, tRXRα is a truncated protein that lacks part of the N-terminal A/B domain of RXRα [41]. Due to the characteristics of its truncated protein, IHC staining analysis cannot distinguish the truncated and full-length forms, and its expression cannot be accurately calculated. Thus, it is not suitable as a predictive biomarker.

Next, we evaluated PI3K/Akt activation markers phosphorylated (p)-Akt (Thr308) and p-Akt (Ser473) as well as cFAM124A and their ability to predict response to sulindac K-80003. It is worth noting that the cFAM124A abundance differed significantly between the response group and non-response group on mIFS staining and IHC staining. (Fig. 5A and D). To further determine whether the optimal sensitive tumor markers we selected originate from tumor-specific sources rather than adjacent tissue, we used adjacent tissue as a reference to adjust the expression levels in the tumor tissue. As expected, in all samples, the expression levels of cFAM124A, p-Akt (Thr308) and p-Akt (Ser473) were higher than those in paracancer tissues (Fig. 5E and F). The fold change value for the tumor relative to the paracancer showed that cFAM124A offers good discrimination between the response group and the non-response group. On the contrary p-Akt (Thr308) and p-Akt (Ser473) showed that discrimination effects that were far inferior to that of cFAM124A, even though the P value for p-Akt (Sre473) reached 0.0325 (Fig. 5G and H). Interestingly, in the value selection, we found that the fold change value for cFAM124A was less than 2 for the non-responsive group, while a value greater than 2 corresponded to a responsive group. Therefore, we propose that the fold change value of 2 may be the cut-off value to distinguish groups that will be responsive and non-responsive to K-80003 (Fig. 5G-H). Based on the above analysis, cFAM124A is a practical and effective biomarker for guiding the use of sulindac K-80003 in the sensitization of PDAC to AG chemotherapy.

Open in a separate window

Fig. 5

cFAM124A is the best marker to predict the ability of K-80003 to promote AG sensitivity in PDAC. A-B, Representative multiplex IHC staining for cFAM124A, p-Akt (Thr308), and p-Akt (Ser473) expression in PDAC tissues collected from K-80003 responsive and K-80003 non-responsive groups. Quantification of cFAM124A, p-Akt (Thr308), and p-Akt (Ser473) staining in PDAC tissues collected from K-80003 responsive and K-80003 non-responsive groups. Scale bar, 100 μm. C-D, Representative H&E, FISH staining for cFAM124A, and IHC staining for p-Akt (Thr308) and p-Akt (Ser473) in PDAC tissues collected from K-80003 responsive and K-80003 non-responsive groups. Quantification of cFAM124A, p-Akt (Thr308), and p-Akt (Ser473) staining in PDAC tissues collected from K-80003 responsive and K-80003 non-responsive groups. Scale bar, 100 μm. E-F, Representative H&E, FISH staining for cFAM124A and IHC staining for p-Akt (Thr308) and p-Akt (Ser473) in paracancer tissues collected from K-80003 responsive and K-80003 non-responsive groups. Quantification of cFAM124A, p-Akt (Thr308), and p-Akt (Ser473) staining in paracancer tissues collected from K-80003 responsive and K-80003 non-responsive groups. Scale bar, 100 μm. G, Fold changes in cFAM124A, p-Akt (Thr308) and p-Akt (Ser473) expression levels in PDAC tissues collected from K-80003 responsive and K-80003 non-responsive groups. H, Peak fold changes in cFAM124A, p-Akt (Thr308), and p-Akt (Ser473) expression in different groups. Not significant (ns), *P<0.05; **P<0.01; ***P<0.001)

K-80003 reverses cFAM124A-induced GEM resistance in PDAC through the PI3K/Akt pathway

We next investigated the mechanisms underlying cFAM124A as an accurate marker for predicting the sulindac K-80003 drug response. Western blotting analysis further demonstrated that overexpression of cFAM124A attenuated the GEM-induced apoptosis level among PDAC cells, as indicated by cleaved caspase 3/8 levels, and promoted excessive activation of the PI3K/Akt pathway, as indicated by higher p-Akt (Thr308) and p-Akt (Ser473) (Fig. 6A). We also used a PI3K pan-inhibitor (copanlisib), which prevented aberrant activation of the PI3K/Akt pathway, and the decreased in GEM-induced apoptosis level caused by cFAM124A overexpression (Fig. 6A). Functional studies employing the CCK-8 assay, clonogenic assay, and 3D tumor microsphere apoptosis staining assay provided in vitro evidence (Fig. 6B-D) as well as in vivo evidence (Fig. 6E and Fig. S4A) that additional treatment with a PI3K/Akt inhibitor rescued overexpressed cFAM124A-related GEM resistance. These findings indicate that cFAM124A promotes PDAC GEM resistance by over-activating the PI3K/Akt pathway. In addition, sulindac K-80003 could also reverse the GEM resistance caused by cFAM124A. However, copanlisib caused weight loss in mice, whereas sulindac K-80003 did not (Fig. 6F), which indicates that sulindac K-80003 offers better biosafety.

Open in a separate window

Fig. 6

cFAM124A activates PI3K/Akt pathway through tRXRα to cause GEM resistance in PDAC, and K-80003 can reverse this effect. A, Western blot analysis of Akt, p-Akt (Ser473), p-Akt (Thr308), and cleaved caspase 3/8 expression after 6 h of treatment with different inhibitors and GEM treatment. B, IC₅₀ values for GEM in PDAC cells overexpressing cFAM124A and control cells after 6 h of treatment with different inhibitors and GEM treatment. C, Necrosis in 3D tumor microspheres based on PI staining (red) and after 6 h of treatment with different inhibitors and GEM treatment. Scale bar, 100 μm. D, Colony formation by cells overexpressing cFAM124A after 6 h of treatment with different inhibitors and GEM treatment in 6-well dishes (800 cells/well) for 2 weeks. Each inhibitor, copanlisib (2 nM, pan-PI3K inhibitor) or K-80003 (5 nM, tRXRα-dependent Akt activation inhibitor). Quantitative data are shown on the right. E, Subcutaneous xenograft model of mice in the different groups treated with GEM (40 mg/kg i.p. 2×/week for 4 weeks), copanlisib (1 mg/kg, iv. 2×/week for 4 weeks), or K-80003 (20 mg/ kg i.p. 2×/week for 4 weeks) at 2 weeks after subcutaneous injection of 5×10⁶ cells overexpressing cFAM124A and control cells. Representative images of tumors are shown (n=5). F, Body weights of subcutaneous tumor-bearing mice in the indicated groups (n=5). G, Volcano plot showing upregulated and downregulated protein between EV-PATU8988T and cFAM124A-PATU8988T cells. H, Western blot analysis of RXRα, Akt, p-Akt (Ser473), and p-Akt (Thr308) expression in PDAC cells overexpressing cFAM124A or with cFAM124A knockout and control cells. I, cFAM124A increased RXRα protein degradation: Indicated PDAC cell lines were incubated with CHX for indicated time periods before western blot analysis of RXRα and GAPDH expression. Representative images are shown (left). J, Indicated PDAC cell lines were incubated with MG132 and then with CHX for indicated time periods before western blot analysis of RXRα and GAPDH expression. Representative images are shown (left)

CircRNAs can act by regulating protein production [42]. We performed proteomics analysis to identify changes in the expression of proteins regulating PI3K/Akt signaling upon cFAM124A overexpression. RXRα protein expression was found to be most decreased, and activation of the PI3K/Akt pathway increased after cFAM124A overexpression in PDAC cells. In contrast, cFAM124A knockdown elicited the opposite response in PDAC cells (Fig. 6G-H and Fig. S4C). Interestingly, RXRα mRNA expression was not altered after cFAM124A overexpression in PDAC cells (Fig. S4D). A reporter gene assay showed that cFAM124A also did not affect RXRα promoter activity (Fig. S4E). This finding prompted our investigation to shift to determining the regulatory potential of cFAM124A on RXRα at the protein level. Next, we analyzed the effect of cFAM124A on the RXRα proteasome-dependent (ubiquitinated) degradation pathway [43]. cFAM124A overexpression accelerated RXRα degradation in PATU8988T cells after treatment with the protein synthesis inhibitor cycloheximide (CHX). Interestingly, this accelerated degradation of RXRα could not be abolished by the proteasome inhibitor MG132, which failed to demonstrate that the effect of cFAM124A on the RXRα degradation is proteasome-dependent (Fig. 6I-J and Fig. S4F-S4G). Previous research has shown that RXRα proteins can be hydrolytically cleaved by protein hydrolases (m-calpain and CTSL) to generate truncated proteins [44, 45]. One example is tRXRα, which interacts with the p85α subunit of PI3K to activate the PI3K/Akt pathway [28]. Coincidentally, at the same time we discovered that the GEM-resistance mechanism involves aberrant activation of the PI3K/Akt pathway caused by cFAM124A overexpression, we observed increased tRXRα expression on western blotting analysis (Fig. 6H). Collectively, we found that cFAM124A activates the PI3K/Akt pathway through tRXRα, leading to GEM resistance in PDAC, and sulindac K-80003 can reverse this effect.

cFAM124A promotes tRXRα expression by upregulating the CTSL enzyme

These findings led us to hypothesize that: (1) cFAM124A may promote hydrolysis of RXRα into tRXRα, which leads to its accelerated degradation; and (2) tRXRα may be the downstream factor responsible for the cFAM124A-induced excessive activation of the PI3K/AKT pathway that leads to GEM resistance in PDAC. Thus, we investigated whether the promoted hydrolysis of RXRα leads to its accelerated degradation. Interestingly, we found that the addition of a CTSL enzyme inhibitor (Z-FY-CHO) and not an m-calpain enzyme inhibitor (PD150606) restored the decrease in RXRα and increase in tRXRα caused by cFAM124A overexpression (Fig. 7A and Fig. S5A). Meanwhile, treatment with the CTSL inhibitor also restored the accelerated degradation of RXRα protein and the increase in tRXRα caused by cFAM124A (Fig. 7B and Fig. S5B).

Open in a separate window

Fig. 7

cFAM124A upregulates CTSL enzyme expression through bridging effect and promotes an increase in the tRXRα protein level. A, Western blot analysis of RXRα expression after 24 h of treatment with PD150606 (200 nM, m-calpain inhibitor) or ZFY-CHO (10 µM, CTSL inhibitor). Representative images are shown (left). B, Indicated PDAC cell lines were incubated with ZFY-CHO and then with CHX for indicated time periods before western blot analysis of RXRα and GAPDH expression. Representative images are shown (left). C, CTSL enzyme-linked immunosorbent assay (ELISA) in PDAC cells with cFAM124A overexpression or knockout. D, Potential cFAM120A-binding proteins were pulled down in cell lysate by RAP assay; these were incubated with the cFAM124A probe and subsequently visualized by MS and silver staining. E, Venn diagram showing the overlap of potential binding proteins of cFAM124A. F, IGF2BP2 was pulled down by the LacZ probe (control) or cFAM124A probe and cFAM124A mutant. G, IGF2BP2 was pulled down by the CTSL 3ʹ-UTR probe after overexpression of CTSL 3ʹ-UTR. H, Association of cFAM124A with CTSL mRNA on RAP assay. I, IGF2BP2 was pulled down by the CTSL 3ʹ-UTR probe on western blotting in the indicated groups. J, Upper: Schematic of the RNA-binding domain within IGF2BP2 and list of different IGF2BP2 truncation mutants. Lower: Immunoblotting with anti-Flag antibody after RNA pulldown assay in PATU8988T cells using RNA cFAM124A or CTSL mRNA probes. K, Pattern diagram of binding among cFAM124A, CTSL mRNA, and IGF2BP2. L, CTSL mRNA expression in the indicated groups. M, CTSL, Akt, RXRα, p-Akt (Thr308), and p-Akt (Ser473) protein expression in the indicated groups. N, CTSL protein concentrations detected by ELISA in the indicated groups

To further investigate how cFAM124A facilitates hydrolytic cleavage of RXRα in a CTSL-dependent manner, we first investigated the effect of cFAM124A on the CTSL enzyme. Our results indicated that cFAM124A promotes CTSL expression at both the mRNA and protein levels as well as CTSL activity (Fig. 7C and Fig. S5C-S5D). This suggests that cFAM124A may promote the stability of CTSL mRNA, leading to an increase in the CTSL protein level. Competing endogenous RNAs (ceRNAs) often act as miRNA sponges by binding with argonaute-2 (AGO2) to regulate the stability of target mRNAs via a ceRNA-related mechanism [46]. However, we did not detect any interaction between AGO2 and cFAM124A by radioimmunoprecipitation (RIP) assay (Fig. S5E), which rules out a ceRNA-related mechanism from this context. The potential ability of cFAM124A to encode proteins was not predicted by analysis of the circRNADb database (Fig. S5F), which led us to investigate a protein scaffolding role of cFAM124A in regulating the stability of the CTSL mRNA.

We performed an RNA pulldown–MS assay to identify the proteins interacting with cFAM124A. AGO2 was not among the 147 proteins identified as interacting with cFAM124A. To narrow down the candidates, we considered proteins that were both identified to interact with FAM124A using MS and predicted to bind with cFAM124A using the catRAPID, RBPsuite, and RBPmap databases (Fig. 7D-E). This analysis identified insulin-like growth factor 2 RNA-binding protein 2 (IGF2BP2), which is known to stabilize mRNA [47]. Through RNA pulldown, silver staining, immunofluorescence, and RIP-qPCR assays, we confirmed the interaction between cFAM124A and IGF2BP2 (Fig. 7D-F and Fig. S5G). Additionally, cFAM124A expression did not affect the abundance of IGF2BP2 (Fig. S5H). Previous research showed that IGF2BP proteins preferentially bind to the “(U>C) GGAC” consensus [47]. We identified two potential IGF2BP-binding regions (namely, “CGGACU” and “UGGACA”) in the cFAM124A sequence, and simultaneous mutation of both loci abolished the bridging role of the two loci that facilitates the binding of IGF2BP2 to CTSL mRNA (Fig. 7F and Fig. S5I-S5J). In addition, siRNA-mediated silencing of IGF2BP2 led to accelerated degradation of CTSL mRNA and protein levels in vitro (Fig. S5K-S5M).

Next, we identified a potential m6A site on the 3ʹ-untranslated region (UTR) of the CTSL mRNA (Fig. S4N), and then we confirmed the interaction between IGF2BP2 and CTSL mRNA by RNA pulldown assay (Fig. 7G). In addition, RNA antisense purification (RAP) assay using the cFAM124A probe also enriched CTSL mRNA (Fig. 7H). Based on this evidence of the interactions among cFAM124A, CTSL mRNA, and IGF2BP2, we propose a potential regulatory mechanism by which cFAM124A promotes the stability of CTSL mRNA. As expected, cFAM124A overexpression increased the interaction between IGF2BP2 and CTSL mRNA, leading to slower degradation of CTSL mRNA (Fig. 7I).

We further constructed a truncated form of IGF2BP2 to examine IGF2BP2-mediated stabilization of the direct functional domain of CTSL mRNA (the functional threshold for recognition of m6A, known as KH4) and the cFAM124A-dependent indirect facilitation of the functional threshold (the functional threshold for binding by cFAM124A, known as KH1) (Fig. 7J). These results validate our hypothesis that cFAM124A binds to IGF2BP2 to stabilize CTSL mRNA in an m6A-dependent manner, thus playing a bridging role (Fig. 7K).

Notably, mutation of the scaffold site on cFAM124A completely reversed the cFAM124A overexpression-induced increase in CTSL expression at both the mRNA and protein levels (Fig. 7L-M). However, it could only partially reverse the increased CTSL activity, increased tRXRα level, aberrant activation of the PI3K/Akt pathway, and increased GEM resistance caused by cFAM124A overexpression (Fig. 7M-N). Interestingly, the entirely reversed effects on the tRXRα/PI3K/ATK pathway and GEM resistance by small interfering (si)-CTSL treatment suggested that the promoting effect of cFAM124A for PDAC GEM resistance depends not only on its effect on CTSL expression but also on its other effects on CTSL activity (Fig. 7M-N). The present findings indicate that cFAM124A upregulates CTSL mRNA and protein expression through bridging, and cFAM124A also affects CTSL enzyme activity through other mechanisms.

cFAM124A enhances CTSL enzyme activity by disrupting cystatin B (CSTB)

The activity of CTSL is mainly regulated by the endogenous cystatin superfamily members, particularly by stefin A (cystatin A, CSTA) and stefin B (cystatin B, CSTB) [48], which inhibit CTSL activity by binding to the C-terminal of CTSL. cFAM124A overexpression did not affect CSTA or CSTB protein expression (Fig. S6A). We reviewed the cFAM124A-interacting proteins identified through the RNA pulldown–MS assay and observed interactions between cFAM124A and CSTB (Fig. 7E and Fig. 8A). In addition, their interaction was confirmed in the catRAPID database and confirmed through immunofluorescence, RIP, and RNA pulldown assays (Fig. 8B-C and Fig. S5B). Interestingly, cFAM124A overexpression in PATU8988T significantly weakened the CTSL–CSTB interaction. In contrast, the interaction between CTSL and CSTB was strengthened upon cFAM124A knockdown (Fig. 8D-E). This suggests that cFAM124A can interact with CSTB protein to interfere with the binding of CSTB to CTSL, thus enhancing CTSL enzyme activity.

Open in a separate window

Fig. 8

cFAM124A competes with CSTB through bait effect and enhances CTSL enzyme activity. A, MS of CSTB protein. B, CSTB was pulled down by the cFAM124A probe or LacZ probe (control). C, RIP assay showing the association of CSTB with cFAM124A. D-E, Co-IP assay of CSTB and CTSL in PDAC cells with cFAM124A overexpression or knockout. F, Predicted binding regions in cFAM124A for CSTB by CatRAPID. G, After PATU8988T cells were transfected with plasmids for wild-type or truncated cFAM124A overexpression, RNA pulldown assay was performed with cFAM124A-specific probes. H, Co-IP assay of CSTB and CTSL in PDAC cells in different treatment groups. I, Western blot analysis of CTSL, RXRα, Akt, p-Akt (Ser473), and p-Akt (Thr308) protein expression in the indicated groups. J, CTSL concentrations by ELISA in the indicated groups. K, Proposed mechanism by which cFAM124A promotes PDAC chemoresistance via “scaffolding” and “decoys-like” effects. Not significant (ns), *P<0.05; **P<0.01; ***P<0.001

To further characterize how cFAM124A interacts at this competitive site, we predicted the competitive site of cFAM124A that binds to CSTB using the catRAPID database and constructed cFAM124A plasmids with truncated corresponding regions for transfection of PATU8988T cells (Fig. 8F). RNA pulldown and coimmunoprecipitation (co-IP) assays showed that when the 76–210-nt region of cFAM124A was truncated, CSTB protein capture by the circRNA probe was significantly reduced, correlating with increased binding of CSTB to CTSL (Fig. 8G-H). In addition, mutation of the competitive site also attenuated, but not entirely abolished, the increase in tRXRα, aberrant elevation of PI3K/Akt pathway activation, and GEM resistance caused by cFAM124A overexpression, as reflected by results from western blotting analysis, CTSL enzyme activity detection, 3D tumor microsphere staining, and colony formation assay (Fig. 8I-J and Fig. S6C-D). Interestingly, these effects were reversed by simultaneous mutation of the cFAM124A bridge site and the competitive site, (Fig. 8I-J and Fig. S6D-S6E). Together these results suggest that cFAM124A upregulates CTSL expression through IGF2BP2 and by interfering with the inhibition of CTSL enzyme activity by binding to CSTB. In turn, this leads to excessive hydrolytic cleavage of RXRα by CTSL and generates tRXRα which excessively activates the PI3K/Akt pathway and promotes GEM resistance in PDAC.

Discussion

The AG regimen is well tolerated and the first choice for the treatment of advanced PDAC in Asia. However, most patients develop chemotherapy resistance, resulting in poor prognosis. Unlike previous studies, which focused on the exploration of drug resistance mechanisms in pancreatic cancer and the prediction of sensitivity markers, we focused on exploring new treatment strategies for sensitization of PDAC to AG regimens. Considering the clinical limitations of immunotherapy combination regimens, we focused on combination strategies with tumor pathway inhibitors. We used the PDO model and RNA-seq of samples from patients with advanced pancreatic cancer to accurately distinguish the drug-resistant group and drug-sensitive group according to the clinical effects of AG treatment. We confirmed that activation of the PI3K/Akt pathway plays a central role in drug resistance in pancreatic cancer [12]. In addition, we adopted the strategy of “conventional drug in new use” that offers great health and economic benefits and selected the established drug sulindac K-80003, a sulindac-derivative, that inhibits PI3K/Akt. We first confirmed its effectiveness without surgery through five prospectively collected PDO models from drug-resistant patients. We also confirmed K-80003 clinical potential in randomly screened and established PDO models of postoperative drug-resistant patients in internal and external cohorts to expand the sample size. Our results demonstrated that K-80003 could sensitize nearly half of the models. In addition, to identify the population for which sulindac K-80003 was effective, we discovered that cFAM124A is the most sensitive and convenient sensitization biomarker, as it was not only more sensitive than the traditional PI3K/Akt activation markers but also associated with the effect target of K-80003, tRXRα. Thus, our research provides a new practical treatment strategy for the clinical sensitization of PDAC to AG chemotherapy.

Abnormal activation of the PI3K/Akt pathway is closely related to the occurrence and progression of PDAC. We established the PDO model using biopsy specimens of unresected advanced pancreatic cancer. We believe that the results from actual tumor-bearing patients can more accurately reflect the sensitivity and resistance tendencies to the AG regimen. Although it was difficult to construct PDOs from biopsy specimens, we still successfully constructed half of the models. We examined changes in mainstream cancer signaling pathways and identified the central role of the PI3K/Akt pathway in chemotherapy resistance, consistent with previous literature [12, 13]. Activation of the PI3K/Akt pathway could promote chemotherapy resistance in various ways, such as regulating the expression of P-gp and ABC transporters to enhance drug efflux [49–51]. These results reveal the clinical potential of interfering with the PI3K/Akt pathway to achieve chemotherapy sensitization. However, the PI3K/Akt pathway is also critical for normal physiological function [52], and thus, clinical use of PI3K/AKT pathway inhibitors (such as Everolimus) can lead to many clinical adverse reactions [22, 23]. Therefore, we focused on the clinical strategy of repurposing old drugs. Since sulindac K-80003 inhibits PI3K/Akt, we first confirmed that sulindac K-80,003 can promote sensitization to AG in the PDO model from biopsy specimens (3/5). We further expanded the sample size and randomly selected 12 drug-resistant models from the PDO model library of surgical patient specimens in our center and established an external validation cohort of 11 cases. We then found nearly half (11/23) were resistant to AG from the in vivo layer, and the drug-resistant PDO model could achieve chemotherapy sensitization. Based on half of the total sample showing benefit (14/28), we believe that sulindac K-80003 is a potential AG chemotherapy-sensitizing drug for pancreatic cancer. Based on its good safety, we plan to conduct clinical research on suitable patients in the future. However, considering that half of the patients still had a limited sensitization response, it is important to find additional response prediction markers to achieve patient stratification for treatment.

Sulindac K-80003 inhibits the activation of tumor-specific PI3K/Akt signaling by preventing the binding of tRXRα to the p85α subunit of PI3K. Theoretically, sulindac K-80003 is most suitable for patients with high expression of tRXRα and PI3k/Akt signaling markers. We also investigated the possibility of using tRXRα as a marker. However, tRXRα, as a truncated protein of RXRα protein, does not have specific antibodies and is difficult to detect directly through conventional RNA-seq or proteomic sequencing. It is also difficult to distinguish tRXRα from RXRα by IHC, which makes the use of tRXRα as a predictive marker unfeasible.

circRNAs have become one of the first choices for drug treatment markers due to their stable structure, long half-life, and convenient detection methods [30, 31]. Therefore, we explored circRNAs as potential biological markers for sensitizing properties. In prospective samples, we screened and eliminated markers that were consistent with high expression of AG-resistant PDO and were related to the PI3K/Akt pathway. We discovered that cFAM124A represent a potential marker reflecting sensitization by sulindac K-80003. We further verified its reliability by combining internal and external data and found that patients with high expression can achieve chemotherapy sensitization. In addition, we found that cFAM124A is generally more effective than p-Akt (Thr308) and p-Akt (Ser473). In previous studies, only the difference between cancer tissue and adjacent tissue was considered, and the impact of adjacent tissue on cancer was ignored [53]. However, this is very important in practical applications. Therefore, we further used paracancer tissue for correction and applied the fold change value for tumor tissue compared with paracancer tissue to predict whether sulindac K-80003 would be effective. The fold change value for cFAM124A showed good discrimination between the response group and the non-response group. However, p-Akt (Thr308) and p-Akt (Ser473) failed to distinguish the groups, which further demonstrates that cFAM124A is a better marker of true tumor characteristics. Interestingly, a fold change value 2 was used as the cut-off value to distinguish the response to sulindac K-80003. Therefore, we believe that cFAM124A is a reliable and practical biomarker for predicting sensitization to AG chemotherapy in clinical practice. The predictive efficacy of the cut-off value of 2 requires further technical development in real-world clinical studies with large sample sizes.

We next investigated molecular mechanisms underlying cFAM124A effects. We found that overexpression of cFAM124A resulted in a significant decrease in RXRα protein levels. Additional studies using CHX and MG132 inhibition experiments ruled out factors affecting the production and degradation of RXRα protein. Interestingly, we found that RXRα truncated form, tRXRα, was significantly increased. We demonstrated that cFAM124A promoted CTSL (a major member of the cysteine protease family, the main proteolytic enzyme that hydrolyzes RXRα to tRXRα) [45] mRNA expression, protein expression, and enzyme activity. circRNAs often exert biological functions by binding to RNA-binding proteins [54]. We demonstrated that cFAM124A binds to IGF2BP2 protein (which functions to stabilize mRNA) and verified that it can bind to the CTSL mRNA 3′-UTR, helping CTSL mRNA and IGF2BP2 protein to form a more stable complex. This was consistent with the fact that most circRNAs exert the function of stabilizing mRNA [55, 56]. Interestingly, we found that interfering only with its binding site could only partially restore the activity of CTSL protease. This led us to speculate that cFAM124A can also affect the enzymatic activity of CTSL through other mechanisms.

Further analysis of the proteins bound by cFAM124A revealed that cFAM124A could also bind to CSTB protein. CSTB is an endogenous inhibitor of the cysteine protease and can negatively regulate the activity of CTSL protease [48]. Using co-IP experiments, we found that cFAM124A sequesters the CSTB protein and interferes with its ability to bind to CTSL, resulting in enhanced CTSL enzyme activity. When interfering with the binding sites of cFAM124A, IGF2BP2, and CSTB at the same time, the expression of tRXRα protein and the abnormal activation state of PI3K/Akt could be restored, which was also consistent with the drug resistance functional phenotype. In summary, our results showed for the first time that some AG-resistant PDAC patients can benefit from K-80003, which improves their sensitivity to AG regimens. This may be due to the high expression of cFAM124A in these cases. High expression of cFAM124A affects the expression and activity of the CTSL enzyme. RXRα is hydrolyzed by CTSL protease into tRXRα, which enhances AKT phosphorylation through interaction with the PI3K subunit p85α and the development of AG resistance. K-80003 directly acts as a site to intervene in the interaction between tRXRα and p85α, inhibit activation of the PI3K/Akt signaling pathway, and weaken AG resistance.

cFAM124A affects the mRNA expression and enzyme activity of CTSL through two mechanisms. We also observed a high positive correlation between the expression levels of cFAM124A and tRXRα, which makes cFAM124A a substitute for tRXRα to guide the use of sulindac K-80003.

This study has certain limitations. We used a prospective PDO model to construct biopsy specimens from patients with advanced pancreatic cancer. Due to the small amount of biopsy samples, the sample size for this part of the study was limited. We prospectively evaluated patients with unresectable advanced stages treated with the AG regimen to define drug resistance. This type of sample is extremely representative. Moreover, we also used PDOs randomly obtained from the retrospective sample library (the sample size was 4 times that of the prospective sample), and the results also confirmed the finding that sulindac K-80003 has the therapeutic potential to overcome AG resistance. The sample library also provides a current sample, and this was one of the largest PDO-based studies of pancreatic cancer. In addition, according to our results, CTSL protease may be used as another potential biomarker of response to sulindac K-80003. However, due to the instability of the protease, its short half-life, its enzymatic activity subject to interference from temperature, and physical and chemical properties, making its in vitro detection difficult. Therefore, we believe that cFAM124A is the optimal biomarker for predicting the ability of K-80003 to overcome AG resistance in PDAC.

Conclusion

The new use of an old drug in combination with chemotherapy offers a safe and effective new strategy to solve the problem of drug resistance in PDAC. The results of this study show that sulindac K-80003, is a safe and effective old drug, that can enhance the sensitivity of pancreatic cancer to AG chemotherapy. This new use of K-80003 provides a new treatment option for clinical use. In addition, we report that cFAM124A is a biological marker that predicts the sensitization effect of sulindac K-80003 in patients with PDAC.

Methods

Electronic supplementary material

Below is the link to the electronic supplementary material.

Author contributions

Shi Chen, Hui-Xing Chen and Li-Qun Chen designed the study. Cheng-Ke Xie and Cheng-Yu Liao performed the study and wrote the paper. Hong-Yi Lin conducted the experiments. Yong-Ding Wu and Feng-Chun Lu participated in data analysis. Xiao-Xiao Huang, Zu-Wei Wang, and Qiao-Wei Li assisted with experiments. Jian-Fei Hu and Cai-Feng Lin collected the tissues. Yin-Hao Chen, and Ge Li provided technical help. All authors read and approved the final manuscript. No potential conflicts of interest were disclosed. Cheng-Ke Xie was responsible for the reliability of all data.

Funding

This work was supported by the Major Scientific Research Project of Young and Middle-aged people of Fujian Provincial Health Commission (2021ZQNZD001, to Shi Chen), the Natural Science Foundation of Fujian Province of China (2020J011007, to Hui-Xing Chen), the Fujian Province Science and Technology Innovation Joint Fund Project (Shi Chen, 2023Y9334), the Fujian Research and Training Grants for Young and Middle-aged Leaders in Healthcare(No.2021(60), to Shi Chen), the Special Funding Project of Fujian Provincial Department of Finance (2100201, to Shi Chen). This work was sponsored by the Key Clinical Specialty Discipline Construction Program of Fujian, P.R.C. This work was supported by Geriatric Center Construction Program of Fujian Provincial Medical Creating Double-high Project. We thank the supports from Prof. Xiao-Kun Zhang of Xiamen University (Xiamen, China). And we thank the supports from Prof. Guo-Zhong Liu of The First Affiliated Hospital of Fujian Medical University (Fuzhou, China). We also thank the technical supports from Panomix Biomedical Tech Co., Ltd. (Suzhou, China), the Anburui BD Laboratory (Fuzhou, China), Gene Denovo Biotechnology Co., Ltd. (Guangzhou, China), Shanghai Outdo Biotech Company (Shanghai, China), GeneChem Co., Ltd. (Shanghai, China), Fuzhou Sunya Biotechnology Co., Ltd. (Fuzhou, China), Servicebio (Wuhan, China), AimingMed Technologies Co., Ltd. (Hangzhou, China) and Keystone Biotechnology Co., Ltd. (Fuzhou, China). Fig. 1A, Fig. 1I, Fig. 2A, Fig. 3A, Fig. 3E, Fig. 3G, Fig. 4A, Fig. 7K and Fig. 8K were Created with BioRender.com released under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International license (https://creativecommons.org/licenses/by-nc-nd/4.0/deed.en).

Data availability

The datasets used and analyzed during the current study are available from the correspondingauthor upon reasonable request.

Declarations

Footnotes

Contributor Information

Li-Qun Chen, Email: nc.ude.uzf@nehcql.

Hui-Xing Chen, Email: moc.361@gnixiuhnehc.

Shi Chen, Email: moc.361@jlawjlwaw.

References